- Home
- RPD vs KNSA Comparison
RPD vs KNSA Comparison
Compare RPD & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- KNSA
- Stock Information
- Founded
- RPD 2000
- KNSA 2015
- Country
- RPD United States
- KNSA United Kingdom
- Employees
- RPD N/A
- KNSA N/A
- Industry
- RPD Computer Software: Prepackaged Software
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- KNSA Health Care
- Exchange
- RPD Nasdaq
- KNSA Nasdaq
- Market Cap
- RPD 1.8B
- KNSA 1.6B
- IPO Year
- RPD 2015
- KNSA 2018
- Fundamental
- Price
- RPD $27.59
- KNSA $23.09
- Analyst Decision
- RPD Buy
- KNSA Strong Buy
- Analyst Count
- RPD 20
- KNSA 6
- Target Price
- RPD $40.67
- KNSA $37.17
- AVG Volume (30 Days)
- RPD 946.1K
- KNSA 634.6K
- Earning Date
- RPD 05-06-2025
- KNSA 04-22-2025
- Dividend Yield
- RPD N/A
- KNSA N/A
- EPS Growth
- RPD N/A
- KNSA N/A
- EPS
- RPD 0.40
- KNSA N/A
- Revenue
- RPD $844,007,000.00
- KNSA $423,239,000.00
- Revenue This Year
- RPD $3.61
- KNSA $37.21
- Revenue Next Year
- RPD $4.82
- KNSA $1.38
- P/E Ratio
- RPD $68.98
- KNSA N/A
- Revenue Growth
- RPD 8.53
- KNSA 56.60
- 52 Week Low
- RPD $26.77
- KNSA $16.56
- 52 Week High
- RPD $50.55
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- RPD 35.80
- KNSA 60.12
- Support Level
- RPD $27.50
- KNSA $22.62
- Resistance Level
- RPD $29.92
- KNSA $23.42
- Average True Range (ATR)
- RPD 1.14
- KNSA 0.75
- MACD
- RPD 0.33
- KNSA -0.01
- Stochastic Oscillator
- RPD 19.62
- KNSA 68.88
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.